143 related articles for article (PubMed ID: 35210824)
1. Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 Possesses Prognostic Significance and Promotes Progression of Papillary Thyroid Cancer.
Niu Y; Huang Y; Dong A; Sun Y
Int J Gen Med; 2022; 15():1509-1516. PubMed ID: 35210824
[TBL] [Abstract][Full Text] [Related]
2. High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma.
Niu Y; Wang W; Jiang X; Huang Y; Yan S; Jiang Y
Jpn J Clin Oncol; 2022 Jul; 52(7):759-765. PubMed ID: 35348687
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma.
Lin G; Ye H; Wang J; Chen S; Chen X; Zhang C
Nephron; 2019; 141(4):256-264. PubMed ID: 30602154
[TBL] [Abstract][Full Text] [Related]
4. The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis.
Shimonosono M; Arigami T; Yanagita S; Matsushita D; Uchikado Y; Kijima Y; Kurahara H; Kita Y; Mori S; Sasaki K; Omoto I; Maemura K; Uenosono Y; Ishigami S; Natsugoe S
Oncotarget; 2018 Apr; 9(31):22069-22078. PubMed ID: 29774123
[TBL] [Abstract][Full Text] [Related]
5. Clinical Value of Human Endogenous Retrovirus-H Long Terminal Repeat Associating 2 (HHLA2) in Small Cell Lung Cancer.
Zhang X; Qin Y; Chen X; Xiong M; Shu S
Technol Cancer Res Treat; 2024; 23():15330338241240683. PubMed ID: 38613340
[No Abstract] [Full Text] [Related]
6. HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.
Wei L; Tang L; Chang H; Huo S; Li Y
Hum Cell; 2020 Jan; 33(1):116-122. PubMed ID: 31552567
[TBL] [Abstract][Full Text] [Related]
7. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L
Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536
[TBL] [Abstract][Full Text] [Related]
8. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract][Full Text] [Related]
9. Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival.
Farrag MS; Ibrahim EM; El-Hadidy TA; Akl MF; Elsergany AR; Abdelwahab HW
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1883-1889. PubMed ID: 34181347
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HHLA2 and CD8 Immunohistochemical Expression in Colorectal Carcinoma and Their Prognostic Significance.
Gawesh ZM; Ibrahim EM; ElKalla HMHR; Awad AAH; Mohamed MA
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4309-4319. PubMed ID: 38156868
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of HHLA2 as a Novel Therapeutic Target for Colorectal Cancer.
Wang H; An Z; Liu Y; Ding G; Deng G; Ji C; Gong Y
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38299402
[TBL] [Abstract][Full Text] [Related]
12. HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma.
Xu Y; Huang Z; Yu X; Li Z; Zheng L; Xu J
Biologics; 2021; 15():329-341. PubMed ID: 34413629
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment.
Luo M; Lin Y; Liang R; Li Y; Ge L
J Inflamm Res; 2021; 14():4217-4228. PubMed ID: 34483677
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of miR-421 predicts poor prognosis and promotes proliferation, migration, and invasion of papillary thyroid cancer cells.
Dong A; Zhang J; Sun W; Hua H; Sun Y
J Chin Med Assoc; 2020 Nov; 83(11):991-996. PubMed ID: 32881717
[TBL] [Abstract][Full Text] [Related]
15. Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
Chen X; Jin J; Zheng L; Sheng Y; Sun J
J BUON; 2021; 26(1):259-265. PubMed ID: 33721460
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W; Chen F; Fei X; Yang X; Lu X
Med Sci Monit; 2018 Oct; 24():7357-7365. PubMed ID: 30319138
[TBL] [Abstract][Full Text] [Related]
17. HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway.
Wang J; Yang K; Yang X; Jin T; Tian Y; Dai C; Xu F
Mol Carcinog; 2024 Apr; ():. PubMed ID: 38578157
[TBL] [Abstract][Full Text] [Related]
18. Expression of ANGPTL2 and its impact on papillary thyroid cancer.
Yang L; Sun R; Wang Y; Fu Y; Zhang Y; Zheng Z; Ji Z; Zhao D
Cancer Cell Int; 2019; 19():204. PubMed ID: 31384179
[TBL] [Abstract][Full Text] [Related]
19. EZH2 upregulation by ERĪ± induces proliferation and migration of papillary thyroid carcinoma.
Xue L; Yan H; Chen Y; Zhang Q; Xie X; Ding X; Wang X; Qian Z; Xiao F; Song Z; Wu Y; Peng Y; Xu H
BMC Cancer; 2019 Nov; 19(1):1094. PubMed ID: 31718595
[TBL] [Abstract][Full Text] [Related]
20. The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma.
Xiao Y; Li H; Yang LL; Mao L; Wu CC; Zhang WF; Sun ZJ
Dis Markers; 2019; 2019():5421985. PubMed ID: 31089395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
